排序方式: 共有6条查询结果,搜索用时 0 毫秒
1
1.
A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer 总被引:4,自引:0,他引:4
Dr. Giancarlo Pizza Caterina De Vinci Diego Cuzzocrea Domenico Menniti Ernesto Aiello Paolo Maver Giuseppe Corrado Piero Romagnoli Ennio Dragoni Giuseppe LoConte Umberto Riolo Aldopaolo Palareti Paolo Zucchelli Vittorio Fornarola Dimitri Viza 《Biotherapy》1996,9(1-3):123-132
As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have
suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA).
These observations prompted us to treat stage D3 prostate cancer patients with an in vitro produced transfer factor (TF) able
to transfer, in vitro and in vivo, CMI against bladder and prostate TAA. Fifty patients entered this study and received one
intramuscular injection of 2–5 units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that complete remission
was achieved in 2 patients, partial remission in 6, and no progression of metastatic disease in 14. The median survival was
126 weeks, higher than the survival rates reported in the literature for patients of the same stage. 相似文献
2.
Emilia Antonucci Daniela Poli Alberto Tosetto Vittorio Pengo Armando Tripodi Nicola Magrini Francesco Marongiu Gualtiero Palareti START-Register 《PloS one》2015,10(5)
START-Register – Survey on anTicoagulated pAtients RegisTer – is an independent, inception-cohort, observational, collaborative database aimed at recording prospectively the clinical history of adult patients starting anticoagulant treatment for any reason and using whatever drug. In this article we present the START-Register and give cross section baseline data focusing on non valvular atrial fibrillation (NVAF). Participants are asked to insert prospectively consecutive patients recorded as electronic file on the web-site of the registry. Required data are: demographic and clinical characteristics of patients, associated risk factors for stroke and bleeding, laboratory routine data, clinical indication for treatment, expected therapeutic range (in cases of treatment with vitamin K antagonists -VKAs). The follow-up is carried out to record: quality of treatment (for patients on VKAs), bleeding complications, thrombotic events, and the onset of any type of associated disease. To date 5252 patients have been enrolled; 97.6% were on VKAs because direct oral anticoagulants (DOAC) have been available in Italy only recently. The median age was 74 years [interquartile range (IQR) 64-80]; males 53.7%. This analysis is focused on the 3209 (61.1%) NVAF patients. Mean CHADS2 score was 2.1±1.1, CHADSVASc score was 3.1±1.3;median age was 76 years (IQR 70-81); 168 patients (5.3%) had severe renal failure [Creatinine clearance (CrCl) <30 ml/min]. Moderate renal failure (CrCl 30-59 ml/min) was found in 1265 patients (39.5%). The analysis of the START-Register data shows that two-third of patients who started chronic anticoagulant treatment had NVAF, one-third of them was > 80 years with high prevalence of renal failure. 相似文献
3.
4.
Dr. Vladimiro Pilotti Mario Mastrorilli Giancarlo Pizza Caterina De Vinci Luciano Busutti Aldopaolo Palareti Giuseppe Gozzetti Antonino Cavallari 《Biotherapy》1996,9(1-3):117-121
The rationale for using transfer factor (TF) in lung cancer patients is that the possibility of improving their cell-mediated
immunity to tumour associated antigens (TAA) may improve their survival. From Jan 1984 to Jan 1995, 99 non-small cell lung
cancer (NSCLC) resected patients were monthly treated with TF, extracted from the lymphocytes of blood bank donors. In the
same period, 257 NSCLC resected patients were considered as non-treated controls. The survival rates of the TF treated group
appear significantly improved both for patients in stages 3a and 3b, and patients with histological subtype “large cell carcinoma”
(P<0.02). Survival of TF treated patients is also significantly higher (P<0.02) for patients with lymphnode involvement (N2
disease). The results of this study suggest that the administration of TF to NSCLC resected patients may improve survival. 相似文献
5.
Dr. Giancarlo Pizza Caterina De Vinci Vittorio Fornarola Aldopaolo Palareti Olavio Baricordi Dimitri Viza 《Biotherapy》1996,9(1-3):175-185
153 patients suffering from recurrent pathologies, i.e. viral infections (keratitis, keratouveitis, genital and labial herpes)
uveitis, cystitis, and candidiasis were treated with in vitro produced transfer factor (TF) specific for HSV-1/2, CMV and
Candida albicans. The cell-mediated immunity of seropositive patients to HSV-1/2 and/or CMV viruses was assessed using the
leucocyte migration inhibition test (LMT) and lymphocyte stimulation test (LST) in presence of the corresponding antigens,
and the frequency of positive tests before, during and after TF administration was studied. The data were stratified per type
of test, antigen and the recipients’ pathology, and statistically evaluated. For the LMT, a total of 960 tests were carried
out for each antigen dilution, 3 different antigen dilutions were used per test. 240/960 tests (25.4%) were found positive
during non-treatment or treatment with unspecific TF, whereas 147/346 tests (42.5%) were found positive when the antigen corresponding
to the specificity of the TF administered to the patient was used (P<0.001). When the data were stratified following pathology,
a significant increased incidence of positive tests during specific treatment was also observed (0.0001<P<0.05). In the LST
(1174 tests), a significant increase of thymidine uptake was observed in the absence of antigen (control cultures), during
treatment with both specific and unspecific TF, but also in the presence of antigen and/or autologous serum during specific
TF administration (P<0.0001). TF administration also significantly increased the soluble HLA class I antigens level in 40
patients studied to this effect. 相似文献
6.
Dr. Giancarlo Pizza Dimitri Viza Caterina De Vinci Aldopaolo Palareti Diego Cuzzocrea Vittorio Fornarola Roberto Baricordi 《Biotherapy》1996,9(1-3):67-72
Forty-four patients suffering from genital (22) and labial (22) herpes were orally treated with HSV-1/2-specific transfer
factor(TF). TF was obtained by in vitro replication of a HSV-1/2-specific bovine dialysable lymphocyte extract. Treatment
was administered bi-weekly the first 2 weeks, and then weekly for 6 months, most patients received 2–3 courses. The total
observation period for all patients before treatment was 26660 days, with 544 relapses, and a relapse index of 61.2, whereas
the cumulative observation period during and after treatment was 16945 days, with a total of 121 relapsing episodes and a
cumulative RI of 21.4 (P<0.0001). Results were equally significant when the 2 groups of patients (labial and genital) were
considered separately. These observations confirm previous results obtained with bovine HSV-specific TF, and warrant further
studies to establish HSV-specific TF as a choice of treatment for preventing herpes recurrences. 相似文献
1